Maintained complete response to talazoparib in a BRCA-2 mutated metastatic luminal breast cancer: case report and review of literature

Maintained complete response to talazoparib in a BRCA-2 mutated metastatic luminal breast cancer: case report and review of literature

PARP inhibitors are progressively becoming a part of our therapeutic arsenal against BRCA-defective tumors, because of their capacity to induce synthetic lethality in cells with a deficiency in the homologous recombination repair system. Olaparib and talazoparib have been approved for metastatic bre...

Full description

Bibliographic Details
Main Authors: Víctor Albarrán, Jesús Chamorro, Javier Pozas, María San Román, Diana Isabel Rosero, Cristina Saavedra, María Gion, Alfonso Cortés, Elena Escalera, Eva Guerra, Elena López Miranda, María Fernández Abad, Noelia Martínez Jañez
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-05-01
Series:Frontiers in Oncology
Subjects:
breast cancer
BRCA
germline
PARP inhibitors
olaparib
talazoparib
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2023.1158981/full

Similar Items

Similar Items